Efficacy And Safety Of Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01072955 |
Recruitment Status
: Unknown
Verified January 2011 by Azidus Brasil.
Recruitment status was: Recruiting
First Posted
: February 22, 2010
Last Update Posted
: January 28, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prevention of Venous Thromboembolism | Biological: Bovine Heparin Biological: Porcine heparin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 104 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Prevention |
Study Start Date : | April 2010 |
Estimated Primary Completion Date : | August 2010 |
Estimated Study Completion Date : | October 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: heparin of bovine origin
5.000UI/mL bottle with 5mL
|
Biological: Bovine Heparin
5.000UI/mL bottle with 5mL
|
Active Comparator: heparin of porcine origin
5000 USP Heparin Units / mL vial with 10 mL vial
|
Biological: Porcine heparin
5000 USP Heparin Units / mL vial with 10 mL vial
|
- Coagulometric parameters markers heparin activity: ACT, APTT and Anti - Xa [ Time Frame: (T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative ]
- Value of the total dose of heparin used, the activity and adequate reversal with the use of protamine. [ Time Frame: (T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who agree with all aspects of the study and sign the FICT;
- Patients of both sexes;
- Patients over the age of 18 years;
- Patients with indication for cardiac surgery requiring cardiopulmonary bypass.
Exclusion Criteria:
- Patients with hematological disorders that compromise the surgical outcome (eg, myeloproliferative disorders, anemia, Hb <11.0 g / dL, platelets <100,000 mm3);
- Patients with disorders of hemostasis (INR> 1.40) (APTTr> 1.40);
- Patients with renal impairment (creatinine> 1.50);
- Patients with deep hyperthermia;
- Liver disease (AST and ALT> 2 times that of the reference value);
- Patients with a history of allergy to heparin or protamine;
- Patients with a history of heparin-induced thrombocytopenia;
- infection (eg endocarditis, septicemia and pneumonia);
- Reoperations;
- Use of antiplatelet agents (clopidogrel and ticlopidine) for less than 7 days;
- Use of aspirin for less than 5 days;
- Use of heparin, low molecular weight less than 24 hours;
- Use of unfractionated heparin for less than 12 hours.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01072955
Contact: Alexandre Frederico, Dr. | +551938293822 | alexandre@lalclinica.com.br |
Brazil | |
LAL Clinica Pesquisa e Desenvolvimento Ltda | Recruiting |
Valinhos, São Paulo, Brazil, 13276-245 | |
Contact: Karina Guerra +551938293822 karina@lalclinica.com.br |
Responsible Party: | Dr. Alexandre Frederico, LAL Clinica |
ClinicalTrials.gov Identifier: | NCT01072955 History of Changes |
Other Study ID Numbers: |
HEPSBCCV1109BOV_EUR version 2 |
First Posted: | February 22, 2010 Key Record Dates |
Last Update Posted: | January 28, 2011 |
Last Verified: | January 2011 |
Additional relevant MeSH terms:
Thromboembolism Venous Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Calcium heparin |
Heparin Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action |